New American Society for Addiction Medicine (ASAM) Advocacy Paper – The Impact of Managed Care on Addiction Treatment

In a document issued in September, ASAM acknowledged that “the current opioid abuse and opioid overdose epidemic in the U.S. is real and it is undoubtedly the cause of increased morbidity and mortality that has surpassed the numbers of people that have been killed as a result of motor vehicle accidents over the past several years. ASAM noted that “while there are many contributing factors involved, the interface of access to appropriated addiction treatment and affordability for the same is fertile ground to begin to plant the seeds for solutions.”

“It is now time that the treatment and managed care communities examine the issues on the treatment side of the equation and develop policies that will lead to better access to clinically indicated treatment and better treat outcomes with patients who suffer from opiate and other addictions.”

ASAM also advocated that “insurers should not dictate or restrict the dosages or length of opioid maintenance treatment that are well established and determined to be efficacious, and in line with the best practices recommendations by the FDA and other agencies (CSAT, NIDA, and NQF) solely to manage cost concerns.”

Source: American Society for Addiction Medicine – September 25, 2012